Karyopharm Therapeutics entered into a forbearance agreement with its lenders and noteholders after defaulting on debt payments, providing the company until at least October 15, 2026, to negotiate with lenders, pursue strategic alternatives, or raise equity. The agreement also allows the company to advance its myelofibrosis program. As part of the agreement, Karyopharm will pay $20.0 million in fees by issuing convertible preferred stock, with the forbearance potentially terminating if the FDA refuses to accept its sNDA for selinexor in myelofibrosis.

Genprex, Inc. announced a strategic development and manufacturing agreement with a leading U.S. based CDMO to scale up production of its diabetes gene therapy program. This collaboration will transition the AAV-based therapeutic candidate, designed for Type 1 and Type 2 diabetes, from research-grade to cGMP-compliant clinical and commercial-ready output. The CDMO will supply drug product for IND-enabling preclinical studies and future clinical trials.

Genprex, Inc. announced a collaboration with Roche Diagnostics to validate TROP2 and PTEN as biomarkers for patient selection in non-small cell lung cancer (NSCLC) clinical trials. This strategic partnership aims to leverage Roche's assay development expertise and a previously FDA Breakthrough Device Designated TROP2 antibody to refine patient identification, potentially shortening recruitment times and enabling more personalized treatment. Genprex anticipates completing validation studies by late 2026 for subsequent integration into its NSCLC clinical program.

Karyopharm Therapeutics is exploring strategic alternatives and potential financing transactions with Centerview Partners to extend its cash runway and maximize stakeholder value. This corporate update follows mixed clinical news, including the failure of its Phase 3 XPORT-EC-042 trial for selinexor in endometrial cancer to meet its primary endpoint, and plans for an August 2026 sNDA submission for accelerated approval of selinexor in myelofibrosis, which is subject to further FDA discussions regarding data for traditional approval conversion.

Werewolf Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2026. Concurrently, the company is exploring strategic alternatives, including potential partnerships, to enhance stockholder value, while also evaluating its cash runway and clinical development timelines.

Lisata Therapeutics, Inc. terminated its merger agreement with Kuva Labs Inc. after Kuva failed to obtain sufficient financing for the tender offer. Kuva is obligated to pay Lisata a $2 million termination fee, and Lisata reserves rights to seek further damages. Lisata's Board will now assess strategic options to enhance stockholder value, including reverse mergers, asset sales, or dissolution, with no assurance of a successful outcome.